SCHEMBL14487679

SCHEMBL14487679

CCOC(=O)Cc1cn(C(=O)OC(C)(C)C)c2cc(C)c(OC)nc12

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
HTR6 P50406 1/20 0.36
KDM4E B2RXH2 4/20 0.34
PDE10A Q9Y233 1/20 0.34
DPP4 P27487 2/20 0.33
PIK3CD O00329 2/20 0.33
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
BRD4 O60885 1/20 0.32
KMT2A Q03164 1/20 0.32
AKR1C3 P42330 1/20 0.31
MTNR1A P48039 3/20 0.31
MTNR1B P49286 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15708569 0.90 L3MBTL1 (0.54) L3MBTL1HTR6KDM4EPDE10ADPP4
SCHEMBL14555779 0.88 L3MBTL1 (0.41) L3MBTL1HTR6KDM4EPDE10APIK3CD
SCHEMBL15724351 0.82 L3MBTL1 (0.57) L3MBTL1HTR6KDM4EPDE10AALDH1A1
SCHEMBL12024535 0.76 L3MBTL1 (0.70) L3MBTL1HTR6KDM4EPDE10AALDH1A1
SCHEMBL14487325 0.72 L3MBTL1 (0.36) L3MBTL1KDM4EDPP4ALDH1A1SMN1; SMN2
SCHEMBL5740608 0.72 L3MBTL1 (1.00) L3MBTL1HTR6KDM4EPDE10AALDH1A1
SCHEMBL28935600 0.72 L3MBTL1 (0.55) L3MBTL1HTR6KDM4EDPP4ALDH1A1
SCHEMBL17883476 0.72 NR1H2 (0.37) L3MBTL1HTR6PDE10A
SCHEMBL30275137 0.71 L3MBTL1 (0.72) L3MBTL1HTR6ALDH1A1SMN1; SMN2KMT2A
SCHEMBL4265552 0.71 L3MBTL1 (0.72) L3MBTL1HTR6ALDH1A1SMN1; SMN2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 US disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 US disclosed
US-10370358-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2019-08-06 US disclosed
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
EP-2729448-B1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2015-09-09 EP disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed
EP-2729448-A1 COMPOUNDS FOR THE TREATMENT OF HIV Gilead Sciences, Inc. (US) 2014-05-14 EP disclosed
WO-2013006738-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2013-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370358-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN L3MBTL1 4307/4885HTR6 4507/4885KDM4E 1590/4885
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN L3MBTL1 4307/4885HTR6 4507/4885KDM4E 1590/4885
US-11034668-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN L3MBTL1 4307/4885HTR6 4507/4885KDM4E 1590/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN L3MBTL1 4307/4885HTR6 4507/4885KDM4E 1590/4885
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN L3MBTL1 4307/4885HTR6 4507/4885KDM4E 1590/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN L3MBTL1 4307/4885HTR6 4507/4885KDM4E 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.